Health Canada

972 articles with Health Canada

• Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living with Beta Thalassemia

  9/29/2020

  Bristol Myers Squibb Canada and Acceleron Pharma Inc. announced that Health Canada has approved REBLOZYL® for the treatment of adult patients with red blood cell transfusion-dependent anemia associated with beta-thalassemia.1 REBLOZYL® is the first and only erythroid maturation agent in Canada, representing a new class of treatment for eligible patients.

• Health Canada Approves REBLOZYL, New Class of Treatment for Adult Patients Living with Beta Thalassemia

  9/29/2020

  REBLOZYL ® is the first and only erythroid maturation  agent approved for use in Canada

• Guide IR Fever Warning Systems Authorized by Health Canada as Medical Device for Uses Related to COVID-19

  9/29/2020

  Guide Sensmart, a world leading manufacturer of infrared thermal imaging systems, has had its IR236 IR Fever Warning System added to the list of authorized medical devices for uses related to COVID-19 by Health Canada.

• Advisory - All strengths of MAR-Diltiazem CD, a drug used to treat angina and hypertension, have been recalled because of dosing concerns

  9/25/2020

  Health Canada is informing Canadians that Marcan Pharmaceuticals has recalled all lots of all MAR-Diltiazem CD products in response to data integrity concerns that could lead to incorrect dosing.

• Axonics® Receives Health Canada Approval of Next Generation Implantable Neurostimulator

  9/21/2020

  Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, announced that Health Canada has approved its next generation rechargeable implantable neurostimulator for the Axonics r-SNM® System.

• Advisory - Unauthorized health products sold on Steroid Hub Canada website may pose serious health risks

  9/18/2020

  Issue Health Canada is warning Canadians about the online retailer Steroid Hub Canada because it is selling unauthorized health products that may pose serious health risks.

• Valeo Pharma Receives Hesperco™ Natural Product License Approval From Health Canada

  9/3/2020

  Valeo Pharma Inc., a Canadian specialty pharmaceutical company, announced that it has received a Natural Product Licence approval from Health Canada authorizing the sale of its bioflavonoid formulation, HespercoTM, in Canada.

• Information Update - Ranitidine products recalled because of a nitrosamine impurity

  8/31/2020

  Pharmascience Inc. is recalling one lot of prescription PMS-Ranitidine as a precaution after tests found NDMA, a nitrosamine impurity, at close to the accepted level.

• Valeo Pharma Has Submitted Hesperco™ Natural Product License Application for Approval to Health Canada

  8/24/2020

  Valeo Pharma Inc., a Canadian specialty pharmaceutical company, announced that it has filed for a Natural Product Licence with Health Canada for its unique bioflavonoid formulation, HespercoTM. HespercoTM capsules contain a powerful antioxidant that can be taken for immune system support.

• Government of Canada begins consultation to better ensure the continuity of supervised consumption sites and services in Canada

  8/20/2020

  Supervised consumption sites and services are an integral part of the Government of Canada's response to the opioid overdose crisis.

• Government of Canada supports a safer drug supply project in Toronto

  8/20/2020

  Temporary Urgent Public Health Need Site also authorized in Toronto shelter to help reduce overdoses during COVID-19

• DUPIXENT® (dupilumab injection) now approved by Health Canada for severe chronic rhinosinusitis with nasal polyposis

  8/18/2020

  First biologic approved in Canada for adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP)

• Government of Canada Invests in Community-based Projects Addressing Challenges of Dementia

  8/13/2020

  Improving the quality of life of people living with dementia and their caregivers in communities across Canada

• Final Update - Public Health Notice: Outbreak of E. coli infections linked to Carnivora brand frozen raw pet food

  8/12/2020

  This notice has been updated to advise that the outbreak appears to be over and the outbreak investigation has been closed.

• Advisory - Remdesivir authorized with conditions for the treatment of patients in Canada with severe COVID-19 symptoms

  7/28/2020

  Health Canada has authorized with conditions the drug remdesivir manufactured by Gilead Sciences Canada, Inc. for the treatment of patients with severe symptoms of COVID-19 who have pneumonia and require extra oxygen to help them breathe.

• Advisory - Status of ranitidine drugs in Canada

  7/23/2020

  Health Canada is providing an update on the status of ranitidine drugs in Canada, including enhanced safety measures the Department is putting in place to detect an impurity called N-nitrosodimethylamine.

• Information Update - Certain hand sanitizers may pose health risks - July 21, 2020

  7/21/2020

    [21-July-2020]   OTTAWA, ON , July 21, 2020 /CNW/ - Health Canada is advising Canadians that the following hand sanitizers made with ethanol or denaturants that are not acceptable for use in hand sanitizers, may pose health risks. Denaturants are added to ethanol to make it unfit for human consumption and, therefore, to avoid the unintentional ingestion of hand sanitizers (particularly by children

• Advisory - Three lots of antidiuretic DDAVP Spray recalled because of potential overdose risk

  7/16/2020

  Issue Ferring Inc. is recalling three lots of DDAVP Spray because the product may contain a higher than labelled dose of the active ingredient and could pose an overdose risk.

• Health Canada Authorizes Interim Use of Dexcom G6 CGM by Pregnant Women in Response to the COVID-19 Pandemic

  7/16/2020

  Last week, Health Canada temporarily authorized the adjunctive use of the Dexcom G6 Continuous Glucose Monitoring system by pregnant women with Type 1, Type 2, or gestational diabetes.

• Advisory - Health Canada Advises Canadians to Stop Using and Selling Two Baby's Journey Infant Napper Products

  7/16/2020

  Health Canada has identified two inclined sleeping products sold between 2016 and 2018, potentially circulating on the second-hand market, that do not meet the safety requirements for bassinets under the Cribs, Cradles and Bassinets Regulations.